ArticleCancer cell2015
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 138 citations in OpenAlex.
- A genomic and epigenomic lens into the biology of acute lymphoblastic leukaemia.Nature reviews. Cancer · 2026Review
- Cytokines, Signaling and Epigenetic Mechanisms: Shaping the Acute Lymphoblastic Leukemia Microenvironment.Cells · 2026Review
- Stem-like memory-T maintenance and differentiation into tissue-resident T cells sustain chronic graft-versus-host disease in mice.Nature communications · 2026Article
- Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia.Science signaling · 2026Article
- Author Correction: Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia.Nature immunology · 2026Article
- ELDA: real-time functional drug profiling in acute lymphoblastic leukemia.Frontiers in oncology · 2026Article
- An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia.Blood neoplasia · 2025Article
- Molecular mechanisms of unique therapeutic potential of CUDC-907 for MEF2D fusion-driven BCP-ALL.Signal transduction and targeted therapy · 2025Article
- Article
- Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure.HemaSphere · 2025Article
- B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and Beyond.International journal of molecular sciences · 2024Review
- Article
- The advances of E2A-PBX1 fusion in B-cell acute lymphoblastic Leukaemia.Annals of hematology · 2024Review
- Proteogenomic profiling uncovers differential therapeutic vulnerabilities betweenHaematologica · 2024Article
- Concepts in B cell acute lymphoblastic leukemia pathogenesis.Journal of leukocyte biology · 2024Review
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.Blood advances · 2024Article
- Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.Genome biology · 2024Article
- Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4/PLC signaling.Nature communications · 2024Article
- RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.Blood advances · 2024Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
38 authors at 11 institutions in 4 countries.
Huimin GengDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Christian HurtzDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Kyle B LenzDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Zhengshan ChenDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Dirk BaumjohannMicrobiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Sarah ThompsonDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Natalya A GolovizninaDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Wei-Yi ChenLaboratory of Biochemistry and Molecular Biology, Rockefeller University, New York, NY 10065, USA; Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 11221, Taiwan.
Jianya HuanDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Dorian LaTochaKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Erica BallabioMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Gang XiaoDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Jae-Woong LeeDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Anne DeucherDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Zhongxia QiDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Eugene ParkDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Chuanxin HuangDepartments of Medicine and Pharmacology, Weill Cornell Medical College, New York, NY 10065, USA.
Rahul NaharDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Soo-Mi KweonDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Seyedmehdi ShojaeeDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Lai N ChanDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Jingwei YuDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Steven M KornblauDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Janetta J BijlHôpital Maisonneuve-Rosemont, Montreal, QC H1T 2M4, Canada.
B Hilda YeDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
K Mark AnselMicrobiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
Elisabeth PaiettaDepartment of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Ari MelnickDepartments of Medicine and Pharmacology, Weill Cornell Medical College, New York, NY 10065, USA.
Stephen P HungerDivision of Pediatric Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Peter KurreDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Papé Family Pediatric Research Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Jeffrey W TynerKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Department of Cell & Developmental Biology, Oregon Health & Science University, Portland, OR 97239, USA.
Mignon L LohPediatric Hematology-Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.
Robert G RoederLaboratory of Biochemistry and Molecular Biology, Rockefeller University, New York, NY 10065, USA.
Brian J DrukerKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Howard Hughes Medical Institute, Portland, OR 97239, USA.
Jan A BurgerDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Thomas A MilneMRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK.
Bill H ChangDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Oregon Health & Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.
Markus MüschenDepartments of Laboratory Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: markus.muschen@ucsf.edu.
University of California, San Francisco · USOregon Health & Science University · USAlbert Einstein College of Medicine · USCornell University · USRockefeller University · USThe University of Texas MD Anderson Cancer Center · USChildren's Hospital of Philadelphia · USHôpital Maisonneuve-Rosemont · CAHoward Hughes Medical Institute · USMRC Weatherall Institute of Molecular Medicine · GBUniversity of Oxford · GB
Funding
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MProject-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$167.6MECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5MUnderstanding the origins of rapid recurrence of pancreatic cancer after resectionP30CA069533 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Luiz Eduardo Bertassoni · 1997 to 2026
$60.5MECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · 2015 to 2026
$41.1MUsing MC1R genotype to impact skin cancer risk behaviors in Hispanics/LatinosU54CA163068 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KENNETH Lynn WRIGHT · 2012 to 2026
$23.1MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MTargeted activation of autoimmune checkpoints in B cell malignanciesR01CA157644 · NCI · YALE UNIVERSITY · PI Markus Müschen · 2011 to 2026
$5.7MFunction and targeting of a stable transcription factor complex in leukemiaR01CA163086 · NCI · ROCKEFELLER UNIVERSITY · PI ROEDER, ROBERT G · 2011 to 2022
$3.6MECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTERU10CA180827 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI LEVINE, ROSS L, MELNICK, ARI M. · 2014 to 2018
$3.0MTranscriptional regulatory mechanisms in B cell development and leukemogenesisR01CA178765 · NCI · ROCKEFELLER UNIVERSITY · PI ROEDER, ROBERT G · 2013 to 2017
$2.8MCancer Research UK 18131Howard Hughes Medical InstituteMedical Research Council MC_UU_12009/6NCI NIH HHS CA163068NCI NIH HHS CA178765NCI NIH HHS P30 CA069533NCI NIH HHS R00 CA151457NCI NIH HHS R00CA151457NCI NIH HHS R01 CA137060NCI NIH HHS R01CA137060NCI NIH HHS R01 CA139032NCI NIH HHS R01CA139032NCI NIH HHS R01 CA157644NCI NIH HHS R01CA157644NCI NIH HHS R01 CA163086NCI NIH HHS R01 CA169458NCI NIH HHS R01CA169458NCI NIH HHS R01 CA172558NCI NIH HHS R01CA172558NCI NIH HHS R01 CA178765NCI NIH HHS R01CA183947NCI NIH HHS U10 CA021115NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180827NCI NIH HHS U10 CA98413NCI NIH HHS U10 CA98543NCI NIH HHS U24 CA114766NCI NIH HHS U24 CA196172Wellcome Trust 101880
Abstract
Studying 830 pre-B ALL cases from four clinical trials, we found that human ALL can be divided into two fundamentally distinct subtypes based on pre-BCR function. While absent in the majority of ALL cases, tonic pre-BCR signaling was found in 112 cases (13.5%). In these cases, tonic pre-BCR signaling induced activation of BCL6, which in turn increased pre-BCR signaling output at the transcriptional level. Interestingly, inhibition of pre-BCR-related tyrosine kinases reduced constitutive BCL6 expression and selectively killed patient-derived pre-BCR(+) ALL cells. These findings identify a genetically and phenotypically distinct subset of human ALL that critically depends on tonic pre-BCR signaling. In vivo treatment studies suggested that pre-BCR tyrosine kinase inhibitors are useful for the treatment of patients with pre-BCR(+) ALL.
Indexed as
Gene Expression Regulation, NeoplasticBasic Helix-Loop-Helix ProteinsClinical Trials as TopicDNA-Binding ProteinsHumansIntracellular Signaling Peptides and ProteinsMolecular Sequence DataPhosphatidylinositol 3-KinasePre-B-Cell Leukemia Transcription Factor 1Precursor Cell Lymphoblastic Leukemia-LymphomaPrecursor Cells, B-LymphoidProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6Signal Transductionsrc-Family KinasesBasic Helix-Loop-Helix ProteinsBCL6 protein, humanDNA-Binding ProteinsIntracellular Signaling Peptides and ProteinsPBX1 protein, humanPhosphatidylinositol 3-KinasePre-B-Cell Leukemia Transcription Factor 1Protein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6src-Family KinasesSyk KinaseSYK protein, humanTCF3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.